Baker Ellis Asset Management LLC Has $8.38 Million Stake in Stryker Corporation $SYK

Baker Ellis Asset Management LLC decreased its position in Stryker Corporation (NYSE:SYK) by 0.9% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 21,175 shares of the medical technology company’s stock after selling 194 shares during the period. Stryker makes up approximately 1.1% of Baker Ellis Asset Management LLC’s holdings, making the stock its 25th biggest position. Baker Ellis Asset Management LLC’s holdings in Stryker were worth $8,377,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Capital A Wealth Management LLC acquired a new position in Stryker in the fourth quarter valued at $26,000. Goodman Advisory Group LLC bought a new stake in Stryker in the first quarter valued at $32,000. City Holding Co. increased its stake in Stryker by 528.6% in the first quarter. City Holding Co. now owns 88 shares of the medical technology company’s stock valued at $33,000 after purchasing an additional 74 shares in the last quarter. Ransom Advisory Ltd bought a new stake in Stryker in the first quarter valued at $37,000. Finally, Smallwood Wealth Investment Management LLC bought a new stake in Stryker in the first quarter valued at $40,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of SYK stock opened at $383.32 on Monday. The stock has a market capitalization of $146.55 billion, a P/E ratio of 50.77, a PEG ratio of 2.76 and a beta of 0.93. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The firm’s 50 day moving average is $388.98 and its 200 day moving average is $379.50. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. The company had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. Stryker’s revenue was up 11.1% compared to the same quarter last year. During the same period in the prior year, the company posted $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, sell-side analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a yield of 0.9%. Stryker’s dividend payout ratio is currently 44.50%.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the sale, the director owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Viju Menon sold 500 shares of the firm’s stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. This trade represents a 3.84% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.20% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on SYK shares. BTIG Research reaffirmed a “buy” rating on shares of Stryker in a research note on Monday, July 14th. Citigroup reissued a “buy” rating and set a $455.00 target price (up from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a research report on Friday, July 18th. Evercore ISI boosted their target price on shares of Stryker from $390.00 to $415.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 8th. Finally, Wells Fargo & Company boosted their target price on shares of Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Fourteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $431.42.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.